Last update 08 May 2025

Anti ILT3 CAR-T cell therapy (Carbiogene Therapeutics)

Overview

Basic Info

Drug Type
CAR-T
Synonyms
Anti ILT3 CAR T cell therapy Carbiogene Therapeutics, antiILT3 CART Carbiogene Therapeutics
Target
LILRB4
Action
inhibitors
Mechanism
LILRB4 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors), Gene transference, T lymphocyte replacements
Therapeutic Areas
NeoplasmsHemic and Lymphatic DiseasesOther Diseases
Active Indication
Acute Monocytic LeukemiaAcute Myelomonocytic Leukemia
Inactive Indication
Acute Myeloid Leukemia
Originator Organization
Zhejiang Carbiogene Therapeutics Co. Ltd.Zhejiang Carbiogene Therapeutics Co. Ltd.
Active Organization
Zhejiang Carbiogene Therapeutics Co. Ltd.Zhejiang Carbiogene Therapeutics Co. Ltd.
Inactive Organization-
License Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Anti ILT3 CAR-T cell therapy (Carbiogene Therapeutics)
NCT04803929
/ RecruitingEarly Phase 1
Clinical Study of Autologous T Cells Modified With ILT3 Chimeric Antigen Receptor for Relapsed/Refractory Acute Myeloid Leukemia (M4/M5)
100 Clinical Results associated with Anti ILT3 CAR-T cell therapy (Carbiogene Therapeutics)
Login to view more data
100 Translational Medicine associated with Anti ILT3 CAR-T cell therapy (Carbiogene Therapeutics)
Login to view more data
100 Patents (Medical) associated with Anti ILT3 CAR-T cell therapy (Carbiogene Therapeutics)
Login to view more data
100 Deals associated with Anti ILT3 CAR-T cell therapy (Carbiogene Therapeutics)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Monocytic LeukemiaPhase 1
China
Zhejiang Carbiogene Therapeutics Co. Ltd.Zhejiang Carbiogene Therapeutics Co. Ltd.
03 Mar 2021
Acute Myelomonocytic LeukemiaPhase 1
China
Zhejiang Carbiogene Therapeutics Co. Ltd.Zhejiang Carbiogene Therapeutics Co. Ltd.
03 Mar 2021
Acute Myeloid LeukemiaPreclinical
China
Zhejiang Carbiogene Therapeutics Co. Ltd.Zhejiang Carbiogene Therapeutics Co. Ltd.
10 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free